Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation
- PMID: 35549799
- PMCID: PMC9679915
- DOI: 10.1080/10428194.2022.2074993
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation
Abstract
There is increasing evidence that social infrastructure and a healthy social network can improve cancer survival. Mayo Clinic has an outpatient stem cell transplantation program for myeloma. Safe outpatient transplantation requires a caregiver to be present. Patients lacking a caregiver are transplanted as an inpatient. We reviewed outcomes on over 2000 patients with multiple myeloma, 2103 transplanted as an outpatient compared with 41 hospitalized for transplantation. Although progression-free survival following transplantation was identical between the two groups, overall survival was shorter in those hospitalized. This suggests that the absence of a caregiver for transplantation is an important surrogate of the social infrastructure associated with poor outcomes in transplanted patients with multiple myeloma.
Keywords: Multiple myeloma; cancer outcomes; family support; social connectedness; stem cell transplantation.
Conflict of interest statement
Conflicts of interest/Competing interests:
MAG personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, and Celgene personal fees from Research to Practice, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health;
Kapoor Sanofi Advisory BoardAbbvie Advisory BoardOncopeptites Advisory BoardPharmacyclics, Advisory BoardBeiGene, Advisory BoardGSK Advisory BoardCellectar Advisory Board
Warsame none;
Hogan none;
Lacy none;
Gonsalves none;
Hayman none
Kourelis none
Buadi none
Muchtar none
Dingli none
Kumar Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, Molecular Templates, Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene, GLH Pharma
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical